GO
| HSI1 | 22,353.33 | -488.29 | 223.62B |
| HSCEI1 | 7,536.31 | -154.03 | 71.32B |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-20 13:16:57 CICC published a research report stating that CSPC PHARMA (01093.HK) announced its third-quarter results, with revenue of RMB6.665 billion, up 0.72% YoY; net profit attributable to shareholders reached RMB982 million, up 1.94% YoY; core net profit was RMB1.055 billion, up 39.04% YoY. Core business performance was in line with market expectations. The broker noted that the core finished drug business remained solid, with the nervous system and digestive metabolism segments driving growth. Third-quarter revenue from the nervous system segment was RMB2.528 billion, up 32.1% YoY; digestive metabolism revenue was RMB351 million, up 41.4% YoY; anti-infective revenue was RMB844 million, up 2.3% YoY; oncology revenue was RMB461 million, down 22.5% YoY; and cardiovascular revenue was RMB404 million, down 14.7% YoY. Third-quarter gross margin was 66.6%, up 1.0 ppts YoY. The selling expense ratio was 24.4%, down 2.0 ppts YoY, while the R&D expense ratio was 24.2%. Licensing income for the first three quarters amounted to RMB6.268 billion, including RMB5.74 billion recognized as the upfront payment from the long-acting peptide cooperation with AstraZeneca, while the remaining RMB2.425 billion has yet to be recognized. Considering the deferred recognition of out-licensing income, the broker lowered CSPC PHARMA's 2026 and 2027 net profit forecasts by 8.4% and 5.4% respectively, to RMB8.665 billion and RMB5.271 billion. It maintained an "Outperform" rating and a TP of HKD12, corresponding to 2026 and 2027 P/E ratios of 13.8x and 21.9x respectively. (da/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |